Trial: 201805206

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Phase

III

Principal Investigator

Huang, Frederick

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov